Ad hoc announcement pursuant to Art. 53 LR
Baar, Switzerland, August 6, 2025
First half of 2025 at a glance:
- Net revenue of CHF 140.0 million (H1/2024: CHF 142.1 million), reflecting a slight increase of 0.2% at constant currencies and a decrease of 1.5% at actual currencies.
- Incoming orders amounted to CHF 156.6 million (H1/2024: CHF 166.1 million), reflecting a decrease of 4.2% at constant currencies and a decrease of 5.7% at actual currencies.
- EBITDA increased by CHF 1.6 million to CHF 12.1 million (H1/2024: CHF 10.5 million), and the EBITDA margin increased by 1.2 percentage points to 8.6% (H1/2024: 7.4%).
- Group profit amounted to CHF 2.2 million (H1/2024: CHF 2.9 million), impacted by predominantly unrealized foreign currency exchange effects.
- Net cash position amounted to CHF 29.5 million (H1/2024: CHF 16.5 million), with a solid equity ratio of 37.9% (H1/2024: 36.7%).
Guidance for the fiscal year 2025: Ascom reconfirms its full-year guidance with low single-digit revenue growth at constant currencies and an EBITDA margin of 9–10%.
Ascom strategy 2025: mid-year momentum and what's next
Ascom's strategy and transformation journey remain unchanged and clear, which is to be one of the leading providers in critical communication and collaboration in the Healthcare and Enterprise sectors. The key focus and achievements in H1/2025 have been:
- Ascom continued to streamline the portfolio and is completing the product containerization, laying the foundation for converged and cloud-based platforms across all segments. This has been a major investment of Ascom over the past three years to further enhance customer value and growth.
- Further efforts were made to improve Ascom's operational efficiency through a cost improvement plan implemented during the second half of 2024 and the first half of 2025.
- Ascom established a new and leaner organization with a stronger customer focus and better cost efficiency:
– The number of regions was reduced from eight to three: Region North, South, and USA & Canada.
– The service, operations, and solutions teams were integrated across regions for better growth and more cost-effective project delivery.
These changes are expected to enable Ascom to
- further strengthen its position in critical communication and collaboration.
- capitalize on growth opportunities in Healthcare and Enterprise markets with software, nurse call, and mobility solutions.
- achieve continued EBITDA accretion year over year.
Key markets in line with expectations
The Ascom North and South regions generated results in H1/2025 in line with expectations. While the region North performed in line with the previous year, the region South showed some revenue growth (at constant currencies), but a decline in incoming orders.
The current market uncertainty in the USA and Canada delayed customer decisions and had a negative impact on order intake and revenue conversion in H1/2025, which was further compounded by the adverse currency evolution of the US Dollar in the first half of 2025.
The book-to-bill ratio remains at a healthy 1.12. Order backlog stood at CHF 309.6 million per 30.6.2025 (CHF 311.5 million per 30.6.2024), a decline of CHF 1.9 million or 0.6%. In constant currencies, order backlog increased by 3.7%.
Increased EBITDA margin
Gross profit in the first half of 2025 amounted to CHF 67.2 million, and the gross margin reached 48.0% (H1/2024: 47.3%). EBITDA came to CHF 12.1 million with an EBITDA margin of 8.6%, an increase of 1.2 percentage points compared to the previous year (H1/2024: CHF 10.5 million with a margin of 7.4%). EBIT was at CHF 5.0 million (H1/2024: CHF 4.0 million). As a result, Ascom closed the first half of 2025 with a Group profit of CHF 2.2 million (H1/2024: CHF 2.9 million).
Solid balance sheet with equity ratio of 37.9%
On 30 June 2025, cash and cash equivalents amounted to CHF 29.5 million. Ascom generated free cash flow of CHF 15.8 million in the first six months (H1/2024: CHF 2.1 million). The cash flow generation was positively impacted by higher cash from operating activities and lower investments. On 30 June 2025, the equity ratio stood at a solid 37.9% (H1/2024: 36.7%).
Share buyback program
To reinforce shareholder value and for the purpose of capital reduction, Ascom has launched a share buyback program up to a maximum of 3 million registered shares and up to a maximum buyback amount of CHF 15.0 million. The program started successfully. The share buyback program is planned to be closed in November 2026.
Guidance for fiscal year 2025
Ascom reconfirms its full-year guidance with low single-digit revenue growth at constant currencies and an EBITDA margin of 9–10%.
KEY FIGURES HALF-YEAR 2025
In CHFm, except % | ||
H1/2025 | H1/2024 | |
Incoming orders | 156.6 | 166.1 |
Order backlog (at the end of the period) | 309.6 | 311.5 |
Net revenue | 140.0 | 142.1 |
Gross profit | 67.2 | 67.2 |
EBIT | 5.0 | 4.0 |
EBIT margin in % | 3.6% | 2.8% |
EBITDA1 | 12.1 | 10.5 |
EBITDA margin in % | 8.6% | 7.4% |
Group profit | 2.2 | 2.9 |
Number of employees (FTE) at 30.06. | 1,370 | 1,433 |
1 EBITDA, earnings before interest, income tax, depreciation, and amortization, see also definition in the 2025 Half-year Report on page 5.
The Ascom Group's Half-Year Report 2025 and the accompanying Half-Year Results Presentation are now available in English at https://www.ascom.com/investors/reports-and-presentations/.
In alignment with our commitment to sustainability, both the Half-Year Report 2025 and the letter to shareholders — which forms an integral part of the report — will be provided exclusively in electronic format to all shareholders via the link above.
The Half-Year Results Conference Webcast 2025 starts on Wednesday, 6 August 2025, at 10.00 a.m. CEST.
The conference can be joined via a live audio webcast with synchronized presentation slides, including Q&A or via conference call, where participants can ask questions after the presentation.
Live-Webcast: Link Live Audio Webcast
Dial In: Link Conference Call
-
从微量到工业化:擎科生物以99.5%+耦合效率定义核酸合成新标杆北京2025年8月6日 美通社 -- 在生命科学与生物医药飞速发展的今天,核酸合成的效率、精度与规模直接决定了研发进程的速度与成本。擎科生物,作为深耕核酸技术领域的先2025-08-06
-
正雅“小小牙医”沉浸式体验活动成功举办为儿童口腔健康启蒙打下坚实基础 上海2025年8月5日 美通社 -- 2025年8月1日,由正雅举办的 “保卫牙齿 小小牙医” 活动热闹开展 。此次活动聚焦儿童口腔健康,通过2025-08-06
-
高力国际携手绿城服务共创可持续未来上海2025年8月6日 美通社 -- 随着全球可持续发展目标与国家高质量发展要求推进,ESG战略布局及落地能力成为有效验证企业及其项目的发展韧性 ,展现其适应环 境变化的2025-08-06
-
科技创新报国路:特莱谱五维空间全息科技的奋斗与担当科技创新报国路: 特莱谱五维空间全息科技的奋斗与担当 特莱谱五维空间全息科技(北京)有限公司创始人 刘 简 一、红色基因与成长之路:初心的萌2025-08-06
-
正剧脸勇闯红色题材赛道 演员刘思博电影、央视、短剧平台成绩齐绽放40集重大革命历史题材电视剧《浴血荣光》正在央视一套黄金档播出,《浴血荣光》以“党的建军路线”为叙事主线,通过史诗般的叙事手法,艺术再现了中国共产党初创时期的2025-08-06